DYRK1B and cancer: Pharmacological inhibition of Dyrk1B leads quiescent cancer cells to re-enter the cell cycle, rendering them vulnerable to conventional cancer treatments, induces apoptosis in cancer cells, and reduces tumor size in vitro and in vivo.